← All trials
NCT02805075
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2016
- Primary completion
- Nov 17, 2017
- Completion date
- Nov 17, 2017
- First posted
- Jun 17, 2016
- Last posted
- Mar 23, 2021
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stanford UniversityLead sponsor
- National Cancer Institute (NCI)Collaborator
- Stanford UniversityOverall official - principal investigator
- Stanford UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.